Compare CLBT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | NAMS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Israel | Netherlands |
| Employees | 1285 | 100 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | CLBT | NAMS |
|---|---|---|
| Price | $12.72 | $33.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $22.50 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.8M | 816.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | $17.96 |
| Revenue Next Year | $17.47 | $540.65 |
| P/E Ratio | $45.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.03 | $15.82 |
| 52 Week High | $20.53 | $42.00 |
| Indicator | CLBT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 52.76 |
| Support Level | $11.76 | $29.73 |
| Resistance Level | $15.09 | $37.43 |
| Average True Range (ATR) | 0.73 | 1.75 |
| MACD | -0.10 | 0.24 |
| Stochastic Oscillator | 47.80 | 57.94 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.